Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central nervous system, conolidine modulates alternate molecular targets. A Science Developments review found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which re